阿立哌唑与溴隐亭治疗抗精神病药物所致高催乳素血症的对照研究

目的：比较小剂量阿立哌唑与溴隐亭治疗抗精神病药物（APS）所致高催乳素血症（HPRL）的疗效及安全性。方法：将120例APS所致高催乳素血症患者随机分为阿立哌唑组和溴隐亭组各60例,在维持原APS治疗方案的基础上,阿立哌唑组合并使用阿立哌唑,嗅隐亭组合并使用溴隐亭,疗程4周。于治疗前、治疗第4周末检测血清催乳素水平。以简明精神病量表（BPRS）及副反应量表（TESS）于治疗前及治疗第1、2、4周末评定原APS治疗疗效及其他不良反应。结果：研究结束时两组血清催乳素水平较治疗前相比差异有显著意义（P〈0.01）;同期两组间比较差异无显著性意义（P〉0.05）;两组BPRS评分治疗前后差异无显著性意义（P〉0.05）;TESS量表显示阿立哌唑组的副反应发生率明显低于溴隐亭组。结论：小剂量阿立哌唑及溴隐亭均能显著改善抗精神病药物所致的HPRL,疗效相当,但阿立哌唑的安全性明显高于溴隐亭。

A control study of Aripiprazole and Bromocryptine in the treatment of antipsychotics - induced hyperprolactinemia

Objective： To compare the efficacy and safety of low dose of Aripiprazole and Bromocryptine in the treatment of antipsychoties - in-duced hyperprolactinemia（HPRL）. Methods ：120 patients with antipsychotics-induced HPRL were randomly divided into Aripiprazole group （n = 60 ） and Bromocryptine group （ n = 60）, based on the original APS treatment, Aripiprazole group was given Aripiprazole, Bromocryptine group was given Bromo-eryptine, treatment for 4 weeks. The plasma PRL levels were measured before teatment and at the 4th weekend. The antipsyehotie efficacy and side effects were assessed with Brief Psychiatric Rating Scale （BPRS）and Treatment Emergent Symptom Scale （TESS）before treatment and at the 1 ,t,2nd,4th week-end. Results： The PRL levels decreased significantly in both groups at the 4th weekend （ P 〈 0.01 ）. There was no significant difference in PRL levels at the 4th weekend in both groups（ P 〉 0.05 ）. There was no significant difference in BPRS total Scores at the 4th weekend in both groups （ P 〉 0.05 ）. The in-cidences and the severity of the adverse reactions in the Bromocryptine group was higher than the Aripiprazole group. Conclusion ： Small doses of Aripi- prazole and Bromoeriptine all can significantly improve the antipsyehotie drugs induced HPRL,but the security of Aripiprazoleis significantly higher than that of Bromoeriptine.